Core Viewpoint - CloudTop New Horizon (01952) has seen a significant increase in stock price, rising over 6% in the afternoon trading session, attributed to the approval of production expansion for its core product, Naisukan, and its inclusion in a global kidney disease management guideline [1] Group 1: Financial Performance - Naisukan's sales revenue reached 520 million yuan in August, marking a record high for monthly sales since its launch, with over 100,000 bottles shipped [1] - The company has raised its revenue guidance for the full year 2025 to 1.2-1.4 billion yuan, with expectations to further increase to 2.4-2.6 billion yuan in 2026 [1] Group 2: Regulatory and Market Developments - The production expansion application for Naisukan was approved by the National Medical Products Administration in early August, allowing the company to resume its sales growth [1] - On September 19, Naisukan was included in the 2025 KDIGO Clinical Practice Guidelines for IgA Nephropathy and IgA Vasculitis, becoming the only recommended treatment for IgA nephropathy in the guideline, indicating a shift in global treatment strategies [1]
港股异动 | 云顶新耀(01952)午后涨超6% 耐赋康扩产后销售显著放量 8月耐赋康销售收入达5.2亿元